Mammoth Biosciences Inc.
Brisbane, CA Doing business as Mammoth Diagnostics
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1000 Marina Blvd #600, Brisbane, CA 94005, USA
- Website
- mammoth.bio
- Founded
- 2017
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | -$2,281,269 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Radx tech - mammoth biosciences detection of sars-COV-2 with the crispr-based detectr platform under radx tech | National Heart Lung and Blood Institute (NIH) | $20,800,000 |
Similar vendors
About the company
Mammoth Biosciences Inc., doing business as Mammoth Diagnostics, is a for-profit corporate entity that harnesses nature's diversity to advance CRISPR products, democratizing disease detection with innovative tests for multiple conditions. Mammoth Biosciences Inc. was registered in SAM.gov on April 20, 2018, and its registration is set to expire on February 17, 2025.
Mammoth Biosciences Inc., through its business name Mammoth Diagnostics, has been awarded a $20.8 million firm fixed price definitive contract by the National Institutes of Health's National Heart, Lung, and Blood Institute to support the RADX Tech program. Under this contract, Mammoth Diagnostics will utilize its CRISPR-based Detectr platform to develop assays for the detection of SARS-CoV-2, the virus that causes COVID-19. The work will be performed in South San Francisco, California over an 18-month period ending in January 2022. The RADX Tech program aims to accelerate diagnostic testing for COVID-19 and future pandemic threats through the NIH's Rapid Acceleration of Diagnostics initiative. Mammoth Biosciences Inc. has also been awarded a sub-contract from MRIGlobal to research, design and develop entire detection workflow including in silico gRNA design tools; nuclease chemistries, including CRISPR/Cas systems, gRNA sequences, nucleases, signal amplification, and reporters; PON devices, including sample processing methods specific to PON and their target panel contents; and manufacture and commercialization of the PON and MMD devices.
Mammoth Biosciences Inc. has been awarded a sub-grant from Emory University for the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) program. Details on the specific goods or services provided under this sub-grant award are not available.
Quick answers
Is Mammoth Biosciences Inc. registered in SAM.gov?
Yes. Mammoth Biosciences Inc.'s SAM.gov registration is active through January 25, 2027.
What is Mammoth Biosciences Inc.'s CAGE code?
Mammoth Biosciences Inc.'s CAGE code is 83CY6, and its Unique Entity ID (UEI) is SMF2ALZMSRA5.
What is Mammoth Biosciences Inc.'s most recent federal award?
Mammoth Biosciences Inc.'s most recent federal contract award is Radx tech - mammoth biosciences detection of sars-COV-2 with the crispr-based detectr platform under radx tech (75N92020C00011), from National Heart Lung and Blood Institute (NIH), on July 30, 2020.
On GovTribe
See Mammoth Biosciences Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors